Peptide profile
Published Data as of
In obese and non-obese male rats, central MOTS-c infusion increased serum testosterone, luteinizing hormone and follicle stimulating hormone.1 In rats, MOTS-c did not change circulating corticosterone or aldosterone compared with saline.2 PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people.3
In obese and non-obese male rats, 14 days of central MOTS-c infusion increased GnRH mRNA and GnRH protein in the hypothalamus.1 Central MOTS-c infusion in these rats increased serum testosterone, luteinizing hormone and follicle stimulating hormone.1 The hormone rise in rats was stronger in non-obese than in obese animals.1
| Measure | Result in rats |
|---|---|
| GnRH mRNA in the hypothalamus of rats | Increased after 14 days of central infusion in rats1 |
| GnRH protein in the hypothalamus of rats | Increased in obese and non-obese rats1 |
| Serum testosterone in rats | Increased in obese and non-obese rats1 |
| Serum luteinizing hormone in rats | Increased in obese and non-obese rats1 |
| Serum follicle stimulating hormone in rats | Increased in obese and non-obese rats1 |
In rats, MOTS-c did not change circulating corticosterone or aldosterone compared with saline.2 After 24 hours of MOTS-c in rats, classical steroidogenic genes in adrenal tissue were unchanged.2
In rats, RNA sequencing of adrenal tissue found 39 differentially expressed genes after MOTS-c compared with saline.2 In rats, MOTS-c raised the purinergic receptor gene P2ry4 by 4.3 fold in adrenal tissue and also upregulated Apoc4.2 In rats, MOTS-c downregulated the adrenal stress markers Bag3 and Smurf2.2
As of November 15, 2026, PepBank holds 459 findings in animals and 238 findings in cells or tissue for MOTS-c, by evidence class.3 These come from 75 publications with findings in animals and 53 with laboratory findings in cells or tissue.3 The MOTS-c studies in PepBank's records include 98 studies with results that gave MOTS-c.3
PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people.3 PepBank's regulatory record lists MOTS-c as not approved for any use, as of October 30, 2026.4
MOTS-c is one of the peptides in PepBank, with 697 results from studies that gave it.3 PepBank holds no findings predicted by a computer model for MOTS-c.3
PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people.3 In obese and non-obese male rats, central MOTS-c infusion increased serum testosterone. The rise in hormone levels was stronger in the non-obese rats than in the obese rats.1
PepBank's regulatory record lists MOTS-c as not approved for any use, as of October 30, 2026. The record gives this status for all places it lists.4 PepBank holds 75 publications with findings in animals for MOTS-c, as of November 15, 2026. It holds no publications with findings in people.3
In rats, MOTS-c did not change circulating corticosterone or aldosterone compared with saline.2 In rats, 24 hours of MOTS-c also left classical steroidogenic genes in adrenal tissue unchanged.2 In rats, RNA sequencing of adrenal tissue found 39 differentially expressed genes after MOTS-c compared with saline.2
In mice, MOTS-c treatment prevented diet-induced obesity and high-fat-diet-induced insulin resistance.6 MOTS-c also enhanced physical performance in young, middle-age and old mice.7 In ovariectomized mice, MOTS-c treatment alleviated bone loss on micro-CT examination and prevented ovariectomy-induced obesity.8,9 In mice given intermittent MOTS-c late in life, healthspan increased.7
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated